DRW Securities’s Corcept Therapeutics CORT Stock Holding History

DRW Securities’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,831	Closed	-$209K	–	1115
2025 Q1	$209K	Buy	+1,831	New	+$111K	0.01%	516

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DRW Securities's CORT Position: Q2 2025 in Review

DRW Securities sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 1,831 shares — an estimated $209K sold.

DRW Securities first reported a position in CORT in Q1 2025 and held it in 1 quarter. The position peaked at $209K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

DRW Securities reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
DRW Securities sold 1,831 Corcept Therapeutics shares in Q2 2025, an estimated $209K.
DRW Securities first reported a position in Corcept Therapeutics in Q1 2025 and held it in 1 quarter.
DRW Securities's Corcept Therapeutics position peaked at $209K in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on DRW Securities's 13F filing for Q2 2025, filed 14 Aug 2025.